Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Core Insights - VolitionRx Limited has appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for its Nu.Q® Discover assays in Japan, enhancing its market presence in the region [1] - The company serves nearly 100 clients globally, including major pharmaceutical and diagnostic firms, and anticipates continued revenue growth for Nu.Q® Discover in 2026 [1] - The Total Accessible Market for relevant companion diagnostics is estimated to be just under $1 billion, indicating significant growth potential [1] Company Developments - The collaboration with MBL is expected to generate interest and data for potential future regulatory applications for diagnostic status in Japan [1] - In 2025, Volition achieved several milestones, including a co-marketing agreement with Hologic Diagenode and the first commercial sale of its High Throughput Synthetic Sepsis method [1] - The Nu.Q® Discover program provides advanced assays for rapid epigenetic profiling, supporting drug developers and researchers in various therapeutic areas [1] Market Context - MBL, established in 1969, is a leading provider of clinical research tools in Japan, focusing on autoimmune diseases and genetic diagnostics [1] - The partnership aims to expand access to nucleosome-based biomarkers for drug developers and researchers, contributing to advancements in personalized medicine [1] - VolitionRx is dedicated to improving disease detection and monitoring through cost-effective blood tests, with a focus on cancers and diseases related to NETosis [1]